Search for: [Abstract = "The aim was to evaluate the levels of PMP and EMP in the plasma patients with AF treated with dabigatran and rivaroxaban, as well as assessment of LALS and its determinants in patients with PAF, PsAF and PmAF. The levels of PMP and EMP were determined in plasma at the time of expected minimum and maximum drug plasma concentrations. Then, cpeak of anticoagulants were determined. LALS was measured using STE. PMP increased after taking dabigatran. The concentration of dabigatran correlated negatively with ∆PMP. In the multivariate model, the independent predictors of ∆PMP were\: cpeak , CAD and PAD. After administration of rivaroxaban, PMP levels were increased, along with an increase in EMP levels. In the multivariable regression analysis, statin therapy was the independent predictor of post\-dose change in PMP levels as also in EMP levels. Patients with PAF had higher LALS when compared to those with PsAF and PmAF. Multiple linear regression showed that the independent predictors of LALS were diastolic BP in the PAF group\; LA area and creatinine in the PsAF group\; AF duration in the PmAF group. Low concentrations of dabigatran may be associated with platelet activation. This mechanism may potentially lead to paradoxical thrombosis in AF patients treated with dabigatran. In patients with AF, administration of rivaroxaban is associated with an increase in PM"]

Number of results: 1